Chemnitz

• A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine … Halted
  2023-505829-14-00 5 2023-12-22 First recurrence glioblastoma
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma Ended
  2024-510972-19-00 4 2025-03-13 Primary mediastinal large B-cell lymphoma (PMBCL)
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a … Ended
  2024-513104-34-00 4 2024-11-25 Major Depressive Disorder
• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended
  2022-502899-23-00 5 2024-04-23 Hepatic Encephalopathy (OHE)
• A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metast … Ended
  2023-505257-40-00 9 2024-04-17 metastatic esophagogastric adenocarcinoma (Stage IV)
• A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended
  2023-505396-71-00 4 2024-03-01 Early Alzheimer’s Disease with Biomarkers of Inflammation
• A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered sub … Ended
  2023-508013-16-00 5 2024-02-26 Birch pollen induced allergic rhinitis or rhinoconjunctivitis
• Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis Ended
  2022-502997-18-00 3 2024-02-02 Atopic Dermatitis
• A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease Ended
  2024-515177-94-00 4 2023-06-21 Parkinson's Disease
• An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogen … Ended
  2022-501537-23-00 4 2023-05-16 Acute myeloid leukemia
• Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment o … Ended
  2022-500538-27-00 10 2023-03-30 Adjunctive therapy to antidepressants for the treatment of major depr
• A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous … Ended
  2024-516300-41-00 5 2023-03-07 Multiple Myeloma
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af … Ended
  2024-510590-14-00 5 2023-03-03 multiple myeloma
• Study to evaluate the efficacy and safety of fedratinib in combination with CC-486 in patients suffering from myelofibrosis in acute phase. Ended
  2024-519227-22-00 9 2022-11-03 Myeloproliferative neoplasm in accelerated phase (MPN-AP)
• A study of MK7684A in Combination with radiation and chemotherapy versus radiation and chemotherapy followed by Durvalumab for patients with … Ended
  2022-502752-31-00 11 2022-04-29 Non-small cell lung cancer
• GRAPPA Ended
  2023-510441-24-00 5 2022-01-28 Graft Vs Host Disease Peripheral Blood Stem Cell Transplantation AML M
• Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffus … Ended
  2023-508259-38-00 5 2021-04-29 Adult patients with relapsed or primary refractory DLBCL
• A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and C … Ended
  2022-502031-20-00 10 2020-12-17 Non-squamous non-small cell lung cancer (NSCLC)
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thro … Ended
  2023-510107-22-00 5 2020-10-27 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070) Ended
  2024-514018-12-00 9 2020-04-06 female and male adult patients with acute myeloid leukemia (AML) at fi
• CIRCULATE Ended
  2023-506715-18-00 5 2019-12-04 colon cancer stage II, rectal cancer stage II
• MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse Ended
  2024-513956-14-00 4 2019-09-16 Acute myeloid leukemia

Showing 169–192 of 200 trials